Stay updated on Pembrolizumab vs. Liver-Directed Therapy in NET Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab vs. Liver-Directed Therapy in NET Clinical Trial page.

Latest updates to the Pembrolizumab vs. Liver-Directed Therapy in NET Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check15 days agoNo Change Detected
- Check23 days agoChange DetectedThe webpage has been updated to include new collaborators, a revised version number, and a specific registry identifier for a clinical trial. However, significant core content regarding the study's objectives and treatment details has been removed.SummaryDifference54%
- Check30 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4, and a date has been added for March 11, 2025, while a date for March 25, 2025, has been removed.SummaryDifference0.2%
- Check37 days agoChange DetectedThe page has been updated to reflect a new last update date of March 25, 2025, and a revision change to version 2.14.3, replacing the previous date of March 11, 2025, and version 2.14.2.SummaryDifference0.1%
- Check52 days agoChange DetectedThe page has updated the study dates and removed outdated information regarding a pilot study involving Pembrolizumab and liver-directed therapies for neuroendocrine tumors.SummaryDifference0.8%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference0.9%
Stay in the know with updates to Pembrolizumab vs. Liver-Directed Therapy in NET Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab vs. Liver-Directed Therapy in NET Clinical Trial page.